IN THE NEWS
CathVision announces the the launch of ECGenius 3.1, an advanced version of the ECGeniusTM System software. The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data.
CathVision Secures FDA Clearance of First & Only EP Recording System with AI Algorithm to Measure Success of Cardiac Ablation
CathVision announces the FDA clearance and commercial availability of the PVI Analyzer and Signal Complexity algorithms. These algorithms are part of the CARDIALYTICS suite of artificial intelligence-powered analytics integrated into the ECGenius System.
CathVision Secures $9 Million in Funding to Accelerate Adoption of ECGenius System & CARDIALYTICS AI-Suite
CathVision announces its most recent financing round of $9 million from investors. The financing will help advance commercial operations driving adoption of the ECGenius™ System, the company’s innovative EP recording technology, and support the continued development of artificial intelligence-powered analytic modules to provide electrophysiologists with unprecedented levels of automated analysis during cardiac ablation procedures.
CathVision’s ECGenius System to be Featured at HRS 2023 Rhythm Theater Symposium and Scientific Sessions
CathVision announces an extensive slate of educational opportunities and scientific sessions at this year’s Heart Rhythm conference demonstrating the significant impact of the ECGenius™ System and potential benefits of AI-based analytics. HRS 2023 is being held May 19-21 in New Orleans; attendees can visit CathVision during the conference at booth 1442.
Progressing Clinical Evidence: CathVision Announces First Patient Enrolled In Persistent AF Study at OLV Hospital Aalst
CathVision announces initial patient enrollment of a follow-on clinical study to demonstrate the value of the Signal Complexity algorithm at OLV Hospital Aalst in Belgium led by Dr. Tom De Potter.
CathVision announces significant milestones demonstrating both the clinical and commercial success of the ECGenius™ System.
CathVision announces the investigation of the Signal Complexity™ algorithm designed to visualize and quantify atrial fibrillation (AF) complexity parameters in patients with persistent AF. Ten patients have been treated to date at NYU Langone Health, one of the nation’s premier academic medical centers.
CathVision Announces Close Of $7.2 Million Financing Round Funding Will Accelerate Commercialization of the ECGenius™ System and Expand Development of Analytic Modules Copenhagen, DENMARK, AUGUST 17, 2022 /PRNewswire/ – CathVision,
CathVision Announces FDA Clearance of ECGenius™ High-Fidelity, Low-Noise EP Recording Technology ECGenius™ Sets a New Standard for ECG Signal Acquisition, Interpretation and Therapy Support COPENHAGEN, Denmark, May 4,
CathVision Announces Completion of Patient Enrollment at First U.S. Clinical Trial Evaluating High-Fidelity, Low-Noise EP Recording Technology
CathVision Announces Completion of Patient Enrollment at First U.S. Clinical Trial Evaluating High-Fidelity, Low-Noise EP Recording Technology University of Vermont Medical Center Initiates Evaluation of the ECGenius™
CathVision Announces First Patient Enrollments in PVISION Multicenter Clinical Study Researchers to Examine Efficacy of Using AI Algorithm to Confirm Pulmonary Vein Isolation COPENHAGEN, Denmark and MINNETONKA, Minn., Oct. 26,
ECGenius System to be Featured at AF Symposium 2023
February 1, 2023
CathVision announces the ECGenius™ System will be featured in a Spotlight Session at the 28th Annual International AF Symposium in Boston, February 2-4, highlighting emerging technologies in cardiac electrophysiology.
CathVision adds U.S. profile to its Board of Directors
March 16, 2021
CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, is announcing a change to its Board of Directors.
Cathvision presents clinical results of first in human study at AF Symposium conference
Jan 29, 2021
CathVision ApS, a medical device company developing a novel cardiac electrophysiology system and artificial intelligence platform to guide ablation therapy for heart rhythm disorders, is featured at the 26thannual international AF Symposium, held online January 29-31st
Cathvision Completes New Investment Round of a Total 13M Euro
May 19, 2020
CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, has completed an investment round of a total 13M euro. Both existing and new investors participated in the round. The proceeds allow the company to begin multi-center clinical studies and complete its FDA approval process for the CathVision Cube system and associated software algorithms.
CathVision Secures 2.2 mEUR from Horizon 2020
Oct 31, 2019
CathVision ApS, a medical device company developing, manufacturing and selling cardiac electrophysiology products, has been awarded a competitive EU grant of 2.2M Euro for the clinical development of its software and clinical decision support platform.
CathVision Expands Board of Directors
May 27, 2019
CathVision ApS, an early stage medical device company… announce today that the addition of two industry leaders to its Boards of Directors. Søren Thestrup-Nielsen MD, and Denis Gestin…
CathVision Raises Venture Funding to Market New EP Recording System
Jul 07, 2017
Medical device company CathVision has signed a multi-million venture investment from Scandinavian-based investors VF Venture and Borean Innovation.
Fonde kaster millioner efter hjerteforstærker
Jul 07, 2017
Cathvision gør sig klar til at erobre et marked på 20 mia. kr. med en hjerteforstærker, der kan være på markedet inden for et par år
Hjerteforstærker får tocifret millioninvestering til ny behandling
Jul 07, 2017
Et nyt produkt skal sikre bedre behandling af hjerterytmeforstyrrelser. Det har sikret virksomheden CathVision en tocifret millioninvestering fra flere fonde.
Dansk hjertefirma rejser friske millioner
Jul 06, 2017
Et opstartsselskab, som står bag nyt innovativt hjerteudstyr, har rejst et tocifret millionbeløb fra to investorer. Pengene skal bruges til en tysk markedslancering.
CathVision Receives ISO 13485 Certification
Oct 02, 2018
CathVision ApS announced today that the company received ISO 13485:2016 certification for Medical Device and Quality Management Systems.
Danish start-up reaches important milestone in the EU
Oct 10, 2018
Danish medtech company Cathvision has received an iso-certification that paves the way for filing an application for CE approval in the EU next year.
Medicoopstart udvider til USA
May 11, 2018
Oprettelsen af et amerikansk datterselskab skal bane vejen til markedet for medicoselskabet CathVision, der forbereder studier og mulig produktion i landet.
CathVision: A Smoother Look at Cardiac Electrograms
Jul 07, 2017
CathVision is a Danish company that aims to reduce noisy electrogram signals during cardiac arrhythmia ablation procedures.